Filana Therapeutics (FRA:PX91) Cyclically Adjusted FCF per Share: €-1.11 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:PX91 Filana Therapeutics Inc FRA:PX91
26 GF Score
Price €0.80
! 2 Warning Signs
View Full Analysis

What is Filana Therapeutics Cyclically Adjusted FCF per Share?

Filana Therapeutics FRA:PX91 -2.67% 26 Cyclically Adjusted FCF per Share is €-1.11 as of Mar. 2026. GuruFocus rates FRA:PX91 with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Filana Therapeutics's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.159. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-1.11 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -2.50% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -7.20% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -6.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Filana Therapeutics was 2.00% per year. The lowest was -16.10% per year. And the median was -8.25% per year.

As of today (2026-07-27), Filana Therapeutics's current stock price is €0.803. Filana Therapeutics's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-1.11. Filana Therapeutics's Cyclically Adjusted Price-to-FCF of today is .


Filana Therapeutics  (FRA:PX91) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Filana Therapeutics Cyclically Adjusted FCF per Share Related Terms


Filana Therapeutics Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Filana Therapeutics's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Filana Therapeutics Cyclically Adjusted FCF per Share Chart

Filana Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.02 -1.16 -1.27 -1.47 -1.27

Filana Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.49 -1.18 -1.21 -1.27 -1.11

FRA:PX91 vs INMB, DYAI, EXOZ: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Filana Therapeutics's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Filana Therapeutics Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Filana Therapeutics's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Filana Therapeutics's Cyclically Adjusted Price-to-FCF falls into.


FRA:PX91
26GF Score
Filana Therapeutics Inc FRA:PX91
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Filana Therapeutics Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Filana Therapeutics's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.159/330.2130*330.2130
=-0.159

Current CPI (Mar. 2026) = 330.2130.

Filana Therapeutics Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.446 241.018 -0.611
201609 -0.380 241.428 -0.520
201612 -0.440 241.432 -0.602
201703 -0.208 243.801 -0.282
201706 -0.435 244.955 -0.586
201709 -0.276 246.819 -0.369
201712 -0.186 246.524 -0.249
201803 -0.201 249.554 -0.266
201806 -0.141 251.989 -0.185
201809 -0.103 252.439 -0.135
201812 -0.029 251.233 -0.038
201903 -0.032 254.202 -0.042
201906 -0.030 256.143 -0.039
201909 -0.039 256.759 -0.050
201912 -0.029 256.974 -0.037
202003 -0.044 258.115 -0.056
202006 -0.030 257.797 -0.038
202009 -0.074 260.280 -0.094
202012 -0.032 260.474 -0.041
202103 -0.051 264.877 -0.064
202106 -0.107 271.696 -0.130
202109 -0.314 274.310 -0.378
202112 -0.177 278.802 -0.210
202203 -0.544 287.504 -0.625
202206 -0.297 296.311 -0.331
202209 -0.573 296.808 -0.637
202212 -0.486 296.797 -0.541
202303 -0.305 301.836 -0.334
202306 -0.440 305.109 -0.476
202309 -0.592 307.789 -0.635
202312 -0.486 306.746 -0.523
202403 -0.399 312.332 -0.422
202406 -0.367 314.175 -0.386
202409 -0.344 315.301 -0.360
202412 -1.216 315.605 -1.272
202503 -0.217 319.799 -0.224
202506 -0.089 322.561 -0.091
202509 -0.110 324.800 -0.112
202512 -0.172 324.054 -0.175
202603 -0.159 330.213 -0.159

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-1.11 mean?
Filana Therapeutics (FRA:PX91) has a Cyclically Adjusted FCF per Share of €-1.11 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Filana Therapeutics and its competitors.
Is Filana Therapeutics' Cyclically Adjusted FCF per Share too high?
Filana Therapeutics' current Cyclically Adjusted FCF per Share is €-1.11. Overall, Filana Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Filana Therapeutics' Cyclically Adjusted FCF per Share compare to INMB and DYAI?
Filana Therapeutics' Cyclically Adjusted FCF per Share of €-1.11 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Filana Therapeutics and its competitors. Filana Therapeutics's current Cyclically Adjusted FCF per Share is €-1.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Filana Therapeutics stock overvalued right now?
Filana Therapeutics (FRA:PX91) has a current Cyclically Adjusted FCF per Share of €-1.11. The current Cyclically Adjusted FCF per Share is €-1.11. Filana Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Filana Therapeutics (FRA:PX91), the current Cyclically Adjusted FCF per Share is €-1.11 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Filana Therapeutics Business Description

Other Exchanges FLNA:USAFLNA:Mexico
Address 6801 N. Capital of Texas Highway, Suite 300, Building 1, Austin, TX, USA, 78731
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.
26GF Score

Get the complete analysis for FRA:PX91

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.80
Price